We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Allogene Therapeutics Inc (ALLO) COM USD0.001

Sell:$3.05 Buy:$3.06 Change: $0.095 (3.20%)
NASDAQ:1.91%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.05
Buy:$3.06
Change: $0.095 (3.20%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.05
Buy:$3.06
Change: $0.095 (3.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Contact details

Address:
210 East Grand Avenue
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 4572700
Website:
https://allogene.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALLO
ISIN:
US0197701065
Market cap:
$498.51 million
Shares in issue:
170.72 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Arie Belldegrun
    Executive Chairman of the Board
  • David Chang
    President, Chief Executive Officer, Co-Founder, Director
  • Geoffrey Parker
    Chief Financial Officer, Executive Vice President, Principal Financial Officer, and Principal Accounting Officer
  • Timothy Moore
    Executive Vice President, Chief Technical Officer
  • Zachary Roberts
    Executive Vice President - Research and Development, Chief Medical Officer
  • Earl Douglas
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.